BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37208732)

  • 41. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
    Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
    Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
    Shi X; Zheng C; Li C; Hou K; Wang X; Yang Z; Liu C; Liu Y; Che X; Qu X
    Cell Biol Int; 2018 Jan; 42(1):53-62. PubMed ID: 28851073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
    Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
    Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
    Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
    PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.
    da Costa Prando E; Cavalli LR; Rainho CA
    Epigenetics; 2011 Dec; 6(12):1413-24. PubMed ID: 22139571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
    Cowan LA; Talwar S; Yang AS
    Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3.
    Meng F; Sun G; Zhong M; Yu Y; Brewer MA
    Int J Oncol; 2013 Aug; 43(2):495-502. PubMed ID: 23709006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells.
    Niinuma T; Kitajima H; Kai M; Yamamoto E; Yorozu A; Ishiguro K; Sasaki H; Sudo G; Toyota M; Hatahira T; Maruyama R; Tokino T; Nakase H; Sugai T; Suzuki H
    Clin Epigenetics; 2019 May; 11(1):70. PubMed ID: 31064417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
    Tellez CS; Grimes MJ; Picchi MA; Liu Y; March TH; Reed MD; Oganesian A; Taverna P; Belinsky SA
    Int J Cancer; 2014 Nov; 135(9):2223-31. PubMed ID: 24668305
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histone deacetylase inhibitors and colorectal cancer: what is new?
    Tampakis A; Tampaki EC; Nebiker CA; Kouraklis G
    Anticancer Agents Med Chem; 2014; 14(9):1220-7. PubMed ID: 25246306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tetrahydrouridine, cytidine analogues, and hemoglobin F.
    DeSimone J; Heller P; Molokie RE; Hall L; Zwiers D
    Am J Hematol; 1985 Mar; 18(3):283-8. PubMed ID: 2579548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
    Ikehata M; Ueda K; Iwakawa S
    Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
    Leone G; Voso MT; Teofili L; Lübbert M
    Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional DNA demethylation is accompanied by chromatin accessibility.
    Pandiyan K; You JS; Yang X; Dai C; Zhou XJ; Baylin SB; Jones PA; Liang G
    Nucleic Acids Res; 2013 Apr; 41(7):3973-85. PubMed ID: 23408854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
    Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
    Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
    Link PA; Baer MR; James SR; Jones DA; Karpf AR
    Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
    Götze S; Coersmeyer M; Müller O; Sievers S
    Int J Oncol; 2014 Oct; 45(4):1715-23. PubMed ID: 25050608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.